GCDFP-15 (EP1582Y) Rabbit Monoclonal Primary Antibody
Specialties: Breast/Gynecological Pathology
Gross cystic disease fluid protein 15 (GCDFP-15) is a glycoprotein localized in the apocrine metaplastic epithelium lining breast cysts and in apocrine glands in the axilla, vulva, eyelid, ear canal, and in salivary glands.1-3 It is not present in normal ductal or lobular epithelium but is present in apocrine metaplasia in the breast. GCDFP-15 positivity is seen in breast carcinomas but not in other common carcinomas such as lung or colorectal carcinoma.4-8
- Mazoujian, G, and R Margolis. "Immunohistochemistry of gross cystic disease fluid protein (GCDFP-15) in 65 benign sweat gland tumors of the skin." The American Journal of dermatopathology vol. 10,1 (1988): 28-35.
- Ansai, S et al. "An immunohistochemical study of lysozyme, CD-15 (Leu M1), and gross cystic disease fluid protein-15 in various skin tumors. Assessment of the specificity and sensitivity of markers of apocrine differentiation." The American Journal of dermatopathology vol. 17,3 (1995): 249-55.
- Mazoujian, G et al. "Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features." The American journal of pathology vol. 110,2 (1983): 105-12.
- Wick, M R et al. "Gross cystic disease fluid protein-15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha-lactalbumin." Human pathology vol. 20,3 (1989): 281-7.
- Liegl, B et al. "Mammary and extramammary Paget's disease: an immunohistochemical study of 83 cases." Histopathology vol. 50,4 (2007): 439-47.
- Bhargava, Rohit et al. "Mammaglobin vs GCDFP-15: an immunohistologic validation survey for sensitivity and specificity." American journal of clinical pathology vol. 127,1 (2007): 103-13.
- Tornos, Carmen et al. "Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary." The American journal of surgical pathology vol. 29,11 (2005): 1482-9.
- Takeda, Yuji et al. "Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors." Archives of pathology & laboratory medicine vol. 132,2 (2008): 239-43.
Specifications
- Reactivity: paraffin
- Control: Breast Carcinoma (Cytoplasmic)
- Dilution Range: 1:100-1:500 *
Package Inserts
IFU
- IVD Rev. 7.0 (CMC25731070)
Have a different keycode?
Click Here
Learn how to obtain your SDS
Ordering Information
For in vitro diagnostic (IVD) use in USA
| 0.1 mL concentrate | 257R-14 |
| 0.5 mL concentrate | 257R-15 |
| 1.0 mL concentrate | 257R-16 |
| 1.0 mL predilute ready-to-use | 257R-17 |
| 7.0 mL predilute ready-to-use | 257R-18 |
For in vitro diagnostic (IVD) use in Canada
| 0.1 mL concentrate | 257R-14 |
| 0.5 mL concentrate | 257R-15 |
| 1.0 mL concentrate | 257R-16 |
| 1.0 mL predilute ready-to-use | 257R-17 |
| 7.0 mL predilute ready-to-use | 257R-18 |
For in vitro diagnostic (IVD) use in Europe
| 0.1 mL concentrate | 257R-14 |
| 0.5 mL concentrate | 257R-15 |
| 1.0 mL concentrate | 257R-16 |
| 1.0 mL predilute ready-to-use | 257R-17 |
| 7.0 mL predilute ready-to-use | 257R-18 |
For research use only (RUO) in Japan
| 0.1 mL concentrate (RUO) | 257R-14-RUO |
| 0.5 mL concentrate (RUO) | 257R-15-RUO |
| 1.0 mL concentrate (RUO) | 257R-16-RUO |
| 1.0 mL predilute ready-to-use (RUO) | 257R-17-RUO |
| 7.0 mL predilute ready-to-use (RUO) | 257R-18-RUO |
To request information on this product in additional countries, please click the button below.
